The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|1|2|115-119

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.1, Iss.2, 2008-05, pp. : 115-119

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sipuleucel-T [Provenge] prolongs prostate-specific antigen (PSA) doubling time in patients with androgen-dependent prostate cancer

By  

Inpharma, Vol. 1, Iss. 1564, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Androgen deprivation therapy for prostate cancer

By Singer Eric A   Golijanin Dragan J   Miyamoto Hiroshi   Messing Edward M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 2, 2008-02 ,pp. : 211-228

Informa Healthcare

Access to resources Recommend Favorite

Pomegranate juice significantly increases prostate specific antigen (PSA) doubling time in patients with prostate cancer and rising PSA levels

By  

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy

By  

Current Drug Targets, Vol. 14, Iss. 4, 2013-04 ,pp. : 420-440

Bentham Science Publishers

Access to resources Recommend Favorite

Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

By Taneja Samir S   Smith Matthew R   Dalton James T   Raghow Sharan   Barnette Gary   Steiner Mitchell   Veverka Karen A  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 293-305

Informa Healthcare

Access to resources Recommend Favorite